Aubry AF et al. |
Recommendations on the Development of a Bioanalytical Assay for 4β-Hydroxycholesterol, an Emerging Endogenous Biomarker of CYP3A Activity. |
2016 |
AAPS J |
pmid:27350147
|
Vanhove T et al. |
Comparative performance of oral midazolam clearance and plasma 4β-hydroxycholesterol to explain interindividual variability in tacrolimus clearance. |
2016 |
Br J Clin Pharmacol |
pmid:27501475
|
Hasan M et al. |
Rapid LC-MS/MS method for the determination of 4-hydroxycholesterol/cholesterol ratio in serum as endogenous biomarker for CYP3A activity in human and foals. |
2016 |
J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. |
pmid:27565568
|
Mao J et al. |
Perspective: 4β-hydroxycholesterol as an emerging endogenous biomarker of hepatic CYP3A. |
2017 |
Drug Metab. Rev. |
pmid:27718639
|
Oh J et al. |
Effects of renal impairment on the pharmacokinetics and pharmacodynamics of a novel dipeptidyl peptidase-4 inhibitor, evogliptin (DA-1229). |
2017 |
Diabetes Obes Metab |
pmid:27761990
|
Hole K et al. |
Impact of genetic and nongenetic factors on interindividual variability in 4β-hydroxycholesterol concentration. |
2017 |
Eur. J. Clin. Pharmacol. |
pmid:27975131
|
Wollmann BM et al. |
4β-Hydroxycholesterol Level in Patients With Rheumatoid Arthritis Before vs. After Initiation of bDMARDs and Correlation With Inflammatory State. |
2017 |
Clin Transl Sci |
pmid:27991741
|
Størset E et al. |
The CYP3A biomarker 4β-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation. |
2017 |
Br J Clin Pharmacol |
pmid:28146606
|
Gjestad C et al. |
4β-Hydroxycholesterol level significantly correlates with steady-state serum concentration of the CYP3A4 substrate quetiapine in psychiatric patients. |
2017 |
Br J Clin Pharmacol |
pmid:28585378
|
Vanhove T et al. |
Pretransplant 4β-hydroxycholesterol does not predict tacrolimus exposure or dose requirements during the first days after kidney transplantation. |
2017 |
Br J Clin Pharmacol |
pmid:28603840
|
Mao J et al. |
Strategy for CYP3A Induction Risk Assessment from Preclinical Signal to Human: a Case Example of a Late-Stage Discovery Compound. |
2017 |
Pharm. Res. |
pmid:28815392
|
Breuer O |
Identification and quantitation of cholest-5-ene-3 beta,4 beta-diol in rat liver and human plasma. |
1995 |
J. Lipid Res. |
pmid:8656065
|
Breuer O et al. |
The oxysterols cholest-5-ene-3 beta,4 alpha-diol, cholest-5-ene-3 beta,4 beta-diol and cholestane-3 beta,5 alpha,6 alpha-triol are formed during in vitro oxidation of low density lipoprotein, and are present in human atherosclerotic plaques. |
1996 |
Biochim. Biophys. Acta |
pmid:8695664
|